Roivant Sciences Ltd.
Roivant Sciences Ltd. is a U.S.-based biopharmaceutical company organized around a portfolio of development-stage medicines and technology-enabled subsidiaries, or "Vants." Its business spans drug discovery, clinical development, and eventual commercialization across autoimmune, inflammatory, and pulmonary disease programs, while also incubating complementary health technology and discovery-stage ventures.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaDrug candidates in development for autoimmune, inflammatory, and pulmonary diseases.
Revenue earned from license agreements and related partnering arrangements.
Fees from technology-related subscriptions and services.
Asiakkaat
Roivant's direct counterparties are primarily pharmaceutical and biotechnology partners, licensees, and collaborators that fund or commercialize its programs. Its eventual end customers are patients and prescribers in specialty disease areas such as autoimmune disorders and pulmonary hypertension, reached through approved medicines or partnered commercialization channels.
License and collaboration counterparties that support development, commercialization, or asset monetization.
End users of therapies such as brepocitinib, IMVT-1402, and batoclimab if approved.
Potential end users of mosliciguat in pulmonary hypertension associated with interstitial lung disease.
Subscribers or users of technology-enabled services that generate recurring or service-based revenue.
Strategia
Roivant's strategy is to build and advance a diversified pipeline through small, focused subsidiaries that can move programs efficiently from discovery to commercialization. It also evaluates acquisitions, in-licensing, and capital allocation actions, including share repurchases, to support portfolio growth and optimize its structure.
Late-stage assets are the main source of future value creation and potential commercialization.
Centralized support and subsidiary autonomy are intended to improve development efficiency.
Cash can be used for development, acquisitions, or shareholder returns depending on opportunity set.
Maantiede
Roivant is headquartered in the United States and operates as a global biopharmaceutical platform through subsidiaries and development partners. Its clinical and regulatory exposure is international because product candidates must satisfy FDA and other health-authority requirements before commercialization, and orphan-drug and exclusivity rules differ across the U.S., Europe, and the U.K.
Riskit
Roivant faces the standard risks of biopharmaceutical development: clinical failure, regulatory delay, and uncertainty around commercialization. Its model also depends on successful execution across multiple subsidiaries, partner relationships, and capital-intensive R&D programs, while future value can be affected by patent, exclusivity, and reimbursement dynamics.
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Medicines cannot be marketed without FDA or other authority approval.
Kohdistuu: All product candidates
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pipeline value depends on positive trial outcomes for multiple product candidates.
Kohdistuu - Commercialization execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Launching approved products requires sales, marketing, reimbursement, and distribution capabilities.
Kohdistuu: Late-stage Vants
- Intellectual property and exclusivity riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Future economics depend on patent protection and regulatory exclusivity periods.
Kohdistuu: Orphan-drug and product exclusivity
- Capital allocation and funding riskVaikutus: KeskitasoTodennäköisyys: Matala
Development programs and acquisitions require substantial capital over time.
Kohdistuu: Pipeline expansion and in-licensing
Kirjanpito
Harkinnanvaraiset erätRevenue depends on when performance obligations and milestones are satisfied.
Vaikutus: Can create lumpy quarterly revenue
Technology-related fees are recognized as services are delivered or used.
Vaikutus: Affects recurring revenue visibility
Investing activity includes purchases and maturities of securities held on balance sheet.
Vaikutus: Can affect other income and liquidity presentation
Asset sales and exits can change reported revenue, assets, and gains/losses.
Vaikutus: Can distort comparability across periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Immunovant, Inc.
IMVT · Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Päivitetty: 24.9.2026